Genome-based bacterial vaccines: current state and future outlook
Genome-based bacterial vaccines: current state and future outlook
Genome-based reverse vaccinology (RV) is a multi-step experimental strategy which starts from in silico analysis of whole genome sequences, from which vaccine candidates can be selected by using bioinformatic algorithms to identify putative protective antigens. In this review, we examine the current state of genome-based RV-engineered vaccines and future applications. The first product of genome-based RV is Bexsero®, a vaccine developed for preventing Neisseria meningitidis serogroup B infection, and the strategy is currently being used for the development of new vaccines for other obdurate and emerging bacterial diseases. Improved sequencing technologies and the ongoing whole-genome sequence analyses of helminths, protozoa, and ectoparasites also currently serve as a basis for an RV strategy to produce new potential vaccines against eukaryotic pathogens. We also highlight an emerging approach-structure-based vaccinology-that exploits the information derived from the determined three-dimensional structures of vaccine candidates. Regardless, genome-based RV and other vaccine discovery platforms still depend on empirical experimental science to glean, from the hundreds of identified antigens from any one pathogen, those that should be combined to produce an effective vaccine.
Schubert-Unkmeir, Alexandra
2977f018-f2bc-447e-b930-8a973c307543
Christodoulides, Myron
eba99148-620c-452a-a334-c1a52ba94078
Schubert-Unkmeir, Alexandra
2977f018-f2bc-447e-b930-8a973c307543
Christodoulides, Myron
eba99148-620c-452a-a334-c1a52ba94078
Abstract
Genome-based reverse vaccinology (RV) is a multi-step experimental strategy which starts from in silico analysis of whole genome sequences, from which vaccine candidates can be selected by using bioinformatic algorithms to identify putative protective antigens. In this review, we examine the current state of genome-based RV-engineered vaccines and future applications. The first product of genome-based RV is Bexsero®, a vaccine developed for preventing Neisseria meningitidis serogroup B infection, and the strategy is currently being used for the development of new vaccines for other obdurate and emerging bacterial diseases. Improved sequencing technologies and the ongoing whole-genome sequence analyses of helminths, protozoa, and ectoparasites also currently serve as a basis for an RV strategy to produce new potential vaccines against eukaryotic pathogens. We also highlight an emerging approach-structure-based vaccinology-that exploits the information derived from the determined three-dimensional structures of vaccine candidates. Regardless, genome-based RV and other vaccine discovery platforms still depend on empirical experimental science to glean, from the hundreds of identified antigens from any one pathogen, those that should be combined to produce an effective vaccine.
This record has no associated files available for download.
More information
Accepted/In Press date: 2013
e-pub ahead of print date: April 2013
Organisations:
Clinical & Experimental Sciences
Identifiers
Local EPrints ID: 353344
URI: http://eprints.soton.ac.uk/id/eprint/353344
ISSN: 1173-8804
PURE UUID: 7ed505f6-4903-4b47-8d11-b23a807f2eab
Catalogue record
Date deposited: 05 Jun 2013 12:16
Last modified: 15 Mar 2024 02:39
Export record
Altmetrics
Contributors
Author:
Alexandra Schubert-Unkmeir
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics